source
- Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositisArgenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drugEndpoints · 14m ago↗ source
- AstraZeneca cans late-stage volrustomig trial after lung cancer setbackAstraZeneca has ended a Phase 3 study of one of its cancer drugs, the latest in a string of setbacks the drugmaker has endured. The company said Monday it was discontinuing ...Endpoints · 17m ago↗ source
- AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus KeytrudaAstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune checkpoint inhibi…